# SODIUM FLUORIDE 5000 PPM SPEARMINT- sodium fluoride paste, dentifrice SODIUM FLUORIDE 5000 PPM FRUIT- sodium fluoride paste, dentifrice Sheffield Pharmaceuticals LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

-----

# SODIUM FLUORIDE 5000 PPM DENTAL CREAM

### SODIUM FLUORIDE 5000 ppm Prescription Dental Cream

### **DESCRIPTION:**

Self-topical neutral fluoride dentifrice containing 1.1% (w/w) sodium fluoride for use as a dental caries preventive in adults and pediatric patients.

### **Active Ingredient:**

Sodium Fluoride 1.1% (w/w)

### **Inactive Ingredients:**

Cellulose Gum, Flavor, Hydrated Silica, Mica, PEG-12, Poloxamer 338, Sodium Benzoate, Sodium Lauryl Sulfate, Sodium Saccharin, Sorbitol, Tartaric Acid, Titanium Dioxide, Tricalcium Phosphate, Water (Purfied), Xanthum gum. This product also contains flavor, FD&C Blue#1(Spearmint only), FD&C Red No. 33 (Fruit only)

### **CLINICAL PHARMACOLOGY:**

Frequent topical applications to the teeth with preparations having a relatively high fluoride content increase tooth resistance to acid dissolution and enhance penetration of the fluoride ion into tooth enamel.

### **INDICATIONS AND USAGE:**

A dental caries preventive; for once daily self-applied topical use. It is well established that 1.1% sodium fluoride is safe and extraordinarily effective as a caries preventive when applied frequently with mouthpiece applicators. 1-4 Sodium Fluoride 5000 ppm dental cream 1.1% sodium fluoride in a squeeze-tube is easily applied onto a toothbrush. This prescription dental cream should be used once daily in place of your regular toothpaste, unless otherwise instructed by your dental professional. May be used whether or not drinking water is fluoridated, since topical fluoride cannot produce fluorosis. (See WARNINGS for exception.)

### **CONTRAINDICATIONS:**

Do not use in pediatric patients under age 6 years unless recommended by a dentist or physician.

### **WARNINGS:**

Prolonged daily ingestion may result in various degrees of dental fluorosis in pediatric patients under age 6 years, especially if the water fluoridation exceeds 0.6 ppm, since younger pediatric patients frequently can not perform the brushing process without significant swallowing. Use in pediatric patients under age 6 years requires special supervision to prevent repeated swallowing of dental cream, which could cause dental fluorosis. Read directions carefully before using.

Keep out of reach of infants and children.

### **PRECAUTIONS:**

Not for systemic treatment. **DO NOT SWALLOW.** 

### Carcinogenesis, Mutagenesis, Impairment of Fertility:

In a study conducted in rodents, no carcinogenesis was found in male and female mice and female rats treated with fluoride at dose levels ranging from 4.1 to 9.1 mg/kg of body weight. Equivocal evidence of carcinogenesis was reported in male rats treated with 2.5 and 4.1 mg/kg of body weight. In a second study, no carcinogenesis was observed in rats, males or females, treated with fluoride up to 11.3 mg/kg of body weight. Epidemiological data provide no credible evidence for an association between fluoride, either naturally occurring or added to drinking water, and risk of human cancer. Fluoride ion is not mutagenic in standard bacterial systems. It has been shown that fluoride ion has potential to induce chromosome aberrations in cultured human and rodent cells at doses much higher than those to which humans are exposed. In vivo data are conflicting. Some studies report chromosome damage in rodents, while other studies using similar protocols report negative results. Potential adverse reproductive effects of fluoride exposure in humans have not been adequately evaluated. Adverse effects on reproduction were reported for rats, mice, fox, and cattle exposed to 100 ppm or greater concentrations of fluoride in their diet or drinking water. Other studies conducted in rats demonstrated that lower concentrations of fluoride (5 mg/kg of body weight) did not result in impaired fertility and reproductive capabilities.

### **Pregnancy:**

Pregnancy Category B. It has been shown that fluoride crosses the placenta of rats, but only 0.01% of the amount administered is incorporated in fetal tissue. Animal studies (rats, mice, rabbits) have shown that fluoride is not a teratogen. Maternal exposure to 12.2 mg fluoride/kg of body weight (rats) or 13.1 mg/kg of body weight (rabbits) did not affect the litter size or fetal weight and did not increase the frequency of skeletal or visceral malformations. Epidemiological studies conducted in areas with high levels of naturally fluoridated water showed no increase in birth defects. Heavy exposure to fluoride during in utero development may result in skeletal fluorosis, which becomes evident in childhood.

### **Nursing Mothers:**

It is not known if fluoride is excreted in human milk. However, many drugs are excreted in milk, and caution should be exercised when products containing fluoride are administered to a nursing woman. Reduced milk production was reported in farm-raised fox when the animals were fed a diet containing a high concentration of fluoride (98-137 mg/kg of body weight). No adverse effects on parturition, lactation, or offspring were seen in rats administered fluoride up to 5 mg/kg of body weight.

### **Pediatric Use:**

The use of Sodium Fluoride 5000 ppm in pediatric age groups 6 to 16 years as a caries preventive is supported by pioneering clinical studies with 1.1% sodium fluoride gels in mouth trays in students age 11-14 years conducted by Englander, et al. <sup>2-4</sup> Safety and effectiveness in pediatric patients below the age of 6 years have not been established. Please refer to the CONTRAINDICATIONS and WARNINGS sections.

### **ADVERSE REACTIONS:**

Allergic reactions and other idiosyncrasies have been rarely reported. To report SUSPECTED ADVERSE REACTIONS, contact Sheffield Pharmaceuticals, LLC at 1-800-222-1087 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

### **OVERDOSAGE:**

Accidental ingestion of large amounts of fluoride may result in acute burning in the mouth and sore tongue. Nausea, vomiting, and diarrhea may occur soon after ingestion (within 30 minutes) and are accompanied by salivation, hematemesis, and epigastric cramping abdominal pain. These symptoms may persist for 24 hours. If less than 5 mg fluoride/kg body weight (i.e., less than 2.3 mg fluoride/lb body weight) have been ingested, give calcium (e.g., milk) orally to relieve gastrointestinal symptoms and observe for a few hours. If more than 5 mg fluoride/kg body weight (i.e., more than 2.3 mg fluoride/lb body weight) have been ingested, induce emesis, give orally soluble calcium (e.g., milk, 5% calcium gluconate or calcium lactate solution) and immediately seek medical assistance. For accidental ingestion of more than 15 mg fluoride/kg of body weight (i.e., more than 6.9 mg fluoride/lb body weight), induce vomiting and admit immediately to a hospital facility. A treatment dose (a thin ribbon) of Sodium Fluoride 5000 ppm contains 2.5 mg fluoride. A 3.4 FLOZ tube (100ml) contains 605 mg fluoride.

### **DOSAGE AND ADMINISTRATION:**

Follow these instructions unless otherwise instructed by your dental professional:

- 1. Adults and pediatric patients 6 years of age or older, apply a thin ribbon of Sodium Fluoride 5000 ppm to a toothbrush. Brush thoroughly once daily for at least two minutes, preferably at bedtime.
- 2. After use, adults expectorate. For best results, do not eat, drink, or rinse for 30 minutes. Pediatric patients, ages 6-16, expectorate after use and rinse mouth thoroughly.

### **How Supplied**

3.4 FLOZ (100ml) NET WT. Tube NDC #11527-730-44

**FRUIT** 

3.4 FLOZ (100ml) NET WT. Tube NDC #11527-750-43

**SPEARMINT** 

### **STORAGE:**

Store at Controlled Room Temperature, 20-25°C (68-77°F).

### **REFERENCES:**

- 1. Accepted Dental Therapeutics, Ed. 40, ADA, Chicago. P. 405-407, 1984.
- 2. Englander, HR, Keyes et al: JADA 75: 638-644, 1967.
- 3. Englander, HR, et al: JADA 78: 783-787, 1969.
- 4. Englander, HR, et al:JADA 83: 354-358, 1971.

### **PRINCIPAL DISPLAY PANEL - 100ml Tube**

**Wentworth** NDC 11527-750-43


Rx only

### **SODIUM FLUORIDE 5000 ppm**

**SPEARMINT** 

1.1% Sodium Fluoride Prescription Strength Toothpaste

NET WT. 3.4 FLOZ. (100ml)



### PRINCIPAL DISPLAY PANEL - 100ml Carton


**Wentworth** NDC 11527-750-43

Rx only

### **Sodium Fluoride 5000 ppm**

**SPEARMINT** 

1.1% Sodium Fluoride Prescription Strength toothpaste NET WT 3.4FLOZ (100ml)



### **PRINCIPAL DISPLAY PANEL - 100ml Tube**

Wentworth

NDC 11527-730-44


Rx Only

### Sodium Fluoride 5000 ppm

**FRUIT** 

1.1% Sodium Fluoride Prescription Toothpaste

3.4 FLOZ (100ml)




### PRINCIPAL DISPLAY PANEL - 100ml Carton

### Wentworth

NDC 11527-730-44

### **Sodium Fluoride 5000 ppm Rx Only**

- 1.1% Sodium Fluoride Prescription Toothpaste FRUIT
- 3.4 FLOZ (100ml)



### SODIUM FLUORIDE 5000 PPM SPEARMINT

sodium fluoride paste, dentifrice

### **Product Information**

Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:11527-750

Route of Administration DENTAL

### **Active Ingredient/Active Moiety**

Ingredient Name

Basis of Strength

SODIUM FLUORIDE (UNII: 8ZYQ1474W7) (FLUORIDE ION - UNII:Q80VPU4080)

SODIUM FLUORIDE (UNII: 8ZYQ1474W7) (FLUORIDE ION - UNII:Q80VPU4080)

SODIUM FLUORIDE (UNII: 8ZYQ1474W7) (FLUORIDE ION - UNII:Q80VPU4080)

# Inactive Ingredients Ingredient Name CARBOXYMETHYLCELLULOSE (UNII: 05JZ17B19X) HYDRATED SILICA (UNII: Y6O7T4G8P9) MICA (UNII: V8A1AW0880) POLYETHYLENE GLYCOL 12000 (UNII: VM53EE110J) POLOXAMER 338 (UNII: F75JV2T505) SODIUM BENZOATE (UNII: 0J245FE5EU) SODIUM LAURYL SULFATE (UNII: 368GB5141J) SACCHARIN SODIUM (UNII: SB8ZUX40TY) SORBITOL (UNII: 506T60A25R)

TARTARIC ACID (UNII: W4888I119H)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
TRICALCIUM PHOSPHATE (UNII: K4C08XP666)	
WATER (UNII: 059QF0KO0R)	
XANTHAN GUM (UNII: TTV12P4NEE)	
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)	

Product Characteristics			
Color	BLUE	Score	
Shape		Size	
Flavor	SPEARMINT	Imprint Code	
Contains			

P	Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:11527-750- 43	1 in 1 CARTON	03/26/2020		
1	100 mL in 1 TUBE; Type 0: Not a Combination Product				

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
UNAPPROVED DRUG OTHER		03/26/2020	

# **SODIUM FLUORIDE 5000 PPM FRUIT**

sodium fluoride paste, dentifrice

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:11527-730
Route of Administration	DENTAL		

Active Ingredient/Active Moiety		
Ingredient Name	<b>Basis of Strength</b>	Strength
Sodium Fluoride (UNII: 8ZYQ1474W7) (FLUORIDE ION - UNII:Q80VPU4080)	FLUORIDE ION	6 mg in 1 mL

Inactive Ingredients		
Ingredient Name	Strength	
CARBOXYMETHYLCELLULOSE (UNII: 05JZ17B19X)		
HYDRATED SILICA (UNII: Y6O7T4G8P9)		

MICA (UNII: V8A1AW0880)	
POLYETHYLENE GLYCOL 12000 (UNII: VM53EE110J)	
<b>POLOXAMER 338</b> (UNII: F75JV2T505)	
SODIUM BENZOATE (UNII: OJ245FE5EU)	
SODIUM LAURYL SULFATE (UNII: 368GB5141J)	
SACCHARIN SODIUM (UNII: SB8ZUX40TY)	
SORBITOL (UNII: 506T60A25R)	
TARTARIC ACID (UNII: W4888I119H)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
TRICALCIUM PHOSPHATE (UNII: K4C08XP666)	
WATER (UNII: 059QF0KO0R)	
XANTHAN GUM (UNII: TTV12P4NEE)	

Product Characteristics			
Color	pink	Score	
Shape		Size	
Flavor	FRUIT	Imprint Code	
Contains			

P	Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:11527-730- 44	1 in 1 CARTON	03/26/2020		
1		100 mL in 1 TUBE; Type 0: Not a Combination Product			

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		03/26/2020	
other		03/20/2020	

# Labeler - Sheffield Pharmaceuticals LLC (151177797)

## **Registrant -** Sheffield Pharmaceuticals LLC (151177797)

<b>Establishment</b>			
Name	Address	ID/FEI	Business Operations
Sheffield Pharmaceuticals LLC		151177797	MANUFACTURE(11527-750, 11527-730), analysis(11527-750, 11527-730)

Revised: 1/2022 Sheffield Pharmaceuticals LLC